Miscellaneous
In this episode, Darrell White, MD, discusses Omidria and how and why it’s used in cataract surgery. He also shares his thoughts on the pass-through status of this product and others and where things are headed. Disclaimer :09 Introduction :20 Financial disclosures :50 What is Omidria, how is it used, and why is it controversial? 1:40 Along came floppy iris syndrome 2:10 The difficulty in predicting when IFIS will occur 5:09 The importance of pupil size in cataract surgery 7:59 Why people are not using Omidria 10:50 What makes Omidria controversial 12:50 Background on the pass-through regulation 13:22 How the price is set and how it is paid for 14:13 A 3-year deadline and use it or lose it funds 18:10 What happens when passthrough ends 20:26 What happened in December 2017? 24:41 The pass-through extension 26:30 Mass confusion over when the 2-year period begins 27:41 Omeros is not the bad actor here 29:47 Congress hasn’t done its job 30:33 A decision needs to be made one way or the other 32:13 And about mitomycin C 33:56